Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself
作者： Qian-Kun Yang , Tong Chen , Shi-Qi Wang , Xiao-Jing Zhang , Zhong-Xiang Yao
DOI: 10.1007/S10456-020-09716-Y
关键词:
摘要: … gets struck in dilemma of reversing multidrug resistance of chemotherapeutic agents while … as targeted therapy in the setting of advanced tumors. Then, we comb through current …
springer.com
sci-hub.se 
researchgate.net 参考文章(136)
Sang Hun Lee, Dongjun Jeong, Yong-Seok Han, Moo Jun Baek, Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Journal of The Korean Surgical Society. ,vol. 89, pp. 1- 8 ,(2015) , 10.4174/ASTR.2015.89.1.1
AeRang Kim, Brigitte C. Widemann, Mark Krailo, Nalini Jayaprakash, Elizabeth Fox, Brenda Weigel, Susan M. Blaney, Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatric Blood & Cancer. ,vol. 62, pp. 1562- 1566 ,(2015) , 10.1002/PBC.25548
Aimee M. Crago, Murray F. Brennan, Principles in Management of Soft Tissue Sarcoma. Advances in Surgery. ,vol. 49, pp. 107- 122 ,(2015) , 10.1016/J.YASU.2015.04.002
J Lewin, K K Khamly, R J Young, C Mitchell, R J Hicks, G C Toner, S Y K Ngan, S Chander, G J Powell, A Herschtal, L Te Marvelde, J Desai, P F M Choong, S A Stacker, M G Achen, N Ferris, S Fox, J Slavin, D M Thomas, A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma British Journal of Cancer. ,vol. 111, pp. 2254- 2261 ,(2014) , 10.1038/BJC.2014.537
S. Tariq Mahmood, Samuel Agresta, Carlos E. Vigil, Xiuhua Zhao, Gang Han, Gina D'Amato, Ciara E. Calitri, Michelle Dean, Christopher Garrett, Michael J. Schell, Scott Antonia, Alberto Chiappori, Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma International Journal of Cancer. ,vol. 129, pp. 1963- 1969 ,(2011) , 10.1002/IJC.25843
Tom Powles, Shanthini M. Crusz, Sequencing Systemic Therapies in Advanced RCC: Is There a Best Strategy? American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 33, pp. 172- 174 ,(2013) , 10.1200/EDBOOK_AM.2013.33.E172
Simon Pacey, Mark J. Ratain, Keith T. Flaherty, Stanley B. Kaye, Lisa Cupit, Eric K. Rowinsky, Chenghua Xia, Peter J. O’Dwyer, I. R. Judson, Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investigational New Drugs. ,vol. 29, pp. 481- 488 ,(2011) , 10.1007/S10637-009-9367-9
Daniel S. Chen, Ira Mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle Immunity. ,vol. 39, pp. 1- 10 ,(2013) , 10.1016/J.IMMUNI.2013.07.012
P.D. Nathan, A. Vinayan, D. Stott, J. Juttla, V. Goh, CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biology & Therapy. ,vol. 9, pp. 15- 19 ,(2010) , 10.4161/CBT.9.1.10340
Lee M. Ellis, Daniel J. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity Nature Reviews Cancer. ,vol. 8, pp. 579- 591 ,(2008) , 10.1038/NRC2403